Aimed Alliance has urged the Institute for Clinical and Economic Review (ICER) to consider patient-defined value of non-small cell lung cancer treatments and warned against using measurement systems that can lead to discrimination against patients, such as “quality-adjusted life years” or QALYs. To read the press release, click here.
Last Updated on May 12, 2020 by Aimed Alliance
